Serogroups of pneumococci that caused bacteremia or meningitis in children were examined from 1981 through 1998 at Boston City Hospital/Boston Medical Center. There were 410 episodes of pneumococcal bacteremia (13-36 cases per year), of which 14 occurred in human immunodeficiency virus (HIV)-infected children and 9 occurred in children with sickle-cell disease. The 7 most common serogroups were 14 (30.7% of isolates), 19 (11.7%), 6 (11%), 18 (10.7%), 9 (7.6%), 23 (7.3%), and 4 (5.6%). The rate of episodes due to serogroups 4, 6, 9, 14, 18, 19, and 23 ranged from 80% to 91.9% during the study period. The rate of episodes due to serogroups 4, 6, 14, 18, 19, and 23 was 84.6% among patients with HIV infection, 100% among patients with sickle-cell disease, and 94.1% among the 18 patients for whom cultures of CSF specimens revealed pneumococcal meningitis. The results demonstrate that type 14 was the dominant pneumococcal serogroup responsible for invasive disease throughout the 18-year study period and that serogroup distribution overall remained constant. A comparison of these findings with historical pediatric data from our institution showed serogroup stability dating back to 1957.
children, it has been shown to decrease serotype-specific invasive disease by 97.4% and invasive disease caused by all serotypes by 89.1% [3] . Pneumococcal conjugate vaccines include a more limited number of antigens of the 90 capsular serotypes of Streptococcus pneumoniae than do polysaccharide vaccines. The selection of antigens to include in a pneumococcal conjugate vaccine is based on the predominant serotypes that cause invasive diseases; however, serotypes of S. pneumoniae may vary according to time, geographic location, type of disease, and host factors such as age, race, and predisposing conditions.
With the introduction of the heptavalent pneumococcal conjugate vaccine in the United States in February 2000, we undertook an analysis of the serogroups of S. pneumoniae isolates from children with invasive diseases who were seen at Boston City Hospital/Boston Medical Center. Our objective was to determine the serogroup distribution during an 18-year period and the correlation of disease-causing serogroups with se- rotypes represented in the new vaccine. We correlated episodes of invasive pneumococcal disease with patient age at the time that the patient presented with bacteremia or meningitis and risk status, which was defined as patients with HIV infection or sickle-cell disease. In addition, the data were correlated with previously reported historical data from our institution [4, 5] .
METHODS
Invasive isolates of S. pneumoniae that were obtained from children 0-17 years of age were identified by a review of the microbiology laboratory logs for 1981 through 1998. Pneumococci were identified first by their morphology in Gramstained smears and by the distinctive colonial morphology on sheep blood agar, and identification was confirmed by use of the optochin test and, in some instances, by use of bile solubility testing; however, principal reliance was placed on Neufeld's reaction, which is the specific capsular swelling (quellung) of pneumococci with pooled typing serum samples (Danish typing serum samples; Statens Serum Institut, Copenhagen), and further identification of the specific type was determined with individual serum samples that constituted the positive reacting pool [6] . Through 1993, isolates were serogrouped at the time of initial identification of the organism. From 1994 through 1998, isolates were frozen, and they were analyzed in 1999. Multiple positive results of cultures for the same patient obtained during the same admission were counted as a single isolate. Isolates were correlated with patient age at the time of presentation with bacteremia or meningitis and underlying high-risk status for HIV infection and sickle-cell disease. Boston Medical Center, formed after the merger of Boston City Hospital and Boston University Medical Center, is a university teaching hospital that serves the inner city of Boston in the northeast of the United States. It is now a 650-bed facility with approximately 2000 pediatric admissions and 25,000 visits to the pediatric emergency department per year. The ethnic makeup of the population at our institution is 55% African American, 25% Hispanic, and 20% white and other ethnic groups.
RESULTS
From January 1981 through December 1998, there were 410 episodes of pneumococcal bacteremia (13 to 36 cases per year) that occurred in children at Boston City Hospital/Boston Medical Center. The serogroup distribution during the study period is shown in table 1. The 7 most common serogroups, in declining frequency, were 14, 19, 6, 18, 9, 23, and 4, with type 14 dominating throughout the study period (figure 1). During the study period, these 7 most common serogroups accounted for 80%-91.9% of all isolates, with only minor changes in rank order (table 2) . Eighty percent of all episodes of bacteremia occurred in children !2 years of age (figure 2).
When assessed according to high-risk status, pneumococcal bacteremia occurred in 14 HIV-infected children and 9 children with sickle-cell disease (table 3) . Only 14% of isolates from HIV-infected children were recovered from children !2 years of age, whereas 43% were from those between 2 and 3 years of age and 43% were from those 3-9 years of age (figure 2).
The rate of episodes due to serogroups 4, 6, 9, 14, 18, 19, and 23 among patients with HIV infection was 84.6% (table 3) . Thirty-three percent of isolates from children with sickle-cell disease were recovered from children younger than 2 years of age, whereas 11% were from those between 2 and 3 years of age and 45% were from those 3-9 years of age (figure 2). All isolates from patients with sickle-cell disease belonged to the serogroups 4, 6, 9, 14, 18, 19, and 23 (table 3) .
During the study period, there were 18 cases of meningitis in which the results of cultures of CSF specimens were positive for pneumococci (table 3) . In contrast to the serogroup distribution for pneumococcal bacteremia, isolates of serogroup 6 were recovered more frequently than were those of serogroup 14. However, overall 94.1% of the CSF isolates belonged to the serogroups 4, 6, 14, 18, 19, and 23 (table 3) .
Pneumococcal isolates have been analyzed at our institution for 170 years. A comparison of the current data with pediatric data from 1957-1969 and 1971-1975 is shown in table 4. Serogroup distribution has remained stable from 1957-1998 with minor changes in rank order, and 83.2% to 90.7% of isolates belonged to serogroups 4, 6, 9, 14, 18, 19, and 23.
DISCUSSION
The polysaccharide capsule of S. pneumoniae is the major virulence factor, and to date, ∼40 serogroups and 90 serotypes have been identified on the basis of antigenic differences in the polysaccharide capsule. Invasive pneumococcal isolates from Boston children indicate that the 7 most common serogroups are 14, 19, 6, 18, 9, 23 , and 4. These data are consistent with findings of a meta-analysis in which several studies from the United States reported that the serogroups of almost 90% of pneumococci isolates that caused invasive disease were from the same 7 serogroups [7] . According to a national prospective pneumococcal surveillance study (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) of serotypes that cause pneumococcal bacteremia, meningitis, or otitis media in children !6 years of age, the 7 most common serotypes (14, 6B, 19F, 18C, 23F, 4, and 9V) accounted for 78% of all isolates that were recovered [8] . A vaccine covering these pneumococcal serotypes would potentially prevent 86% of episodes of bacteremia, 83% of episodes of meningitis, and 65% of episodes of otitis, if the vaccine were 100% effective. In another study, one-half of invasive diseases in children were due to types 6, 14, and 18, and one-half of the episodes of otitis media were caused by 3 other types (19, 23 , and 3) [9] . The currently available pneumococcal polysaccharide vaccine is not protective in children !2 years of age; however, the recently licensed heptavalent pneumococcal conjugate vaccine, which covers serotypes 6B, 9V, 14, 18C, 19F, and 23F, has been shown to be highly effective in preventing invasive disease in young children [3] . Additional data from the country of Finland indicate that immunization with 7V-PnC vaccine reduced the incidence of serotype-specific pneumococcal otitis media by 57% [10] . In the United States, isolation of S. pneumoniae with reduced susceptibility to penicillin increased during the 1980s and 1990s, and multidrug-resistant S. pneumoniae has become a clinical management problem [11] [12] [13] . The most common drug-resistant serotypes are 6B, 9V, 14, 19A, 19F, and 23F [11] . In each region of the world, at least 80% of antibiotic-resistant serotypes currently appear to be represented in 7V-PnC vaccine [7, [14] [15] [16] [17] .
Within the United States, reports indicate a relatively coherent picture of the most common serotypes and likely vaccine candidates; worldwide, however, the prevalence of serotypes varies from country to country and is sometimes significantly different from that in the United States. In Israel and Rwanda, for example, serotypes 1 and 5 are most common [18, 19] , whereas, in the United States, these 2 serotypes account for only 1.3% of isolates from children [8] and for !1% of isolates in our study. Invasive strains of S. pneumoniae isolated from children !5 years of age in Bangladesh (1992) (1993) (1994) (1995) showed that the predominant serotypes were, in descending order, 7F, 12F, 14, 15B, 18, 5, and 22A [20] , which are significantly different from the serotypes that are present in the current heptavalent pneumococcal conjugate vaccine. Although pediatric data from Brazil indicate somewhat more overlap with the serotypes in this conjugate vaccine, several of the most common serotypes that cause invasive disease in Brazil (1, 5, and 19A) would not be included [21] . In the Americas, a multicenter, multicountry surveillance study that involved children !5 years of age found a gradual decrease in the prevalence of types 1 and 5 and a gradual increase in the prevalence of type 23F when moving northward [22] . Serogroup 1 has also been reported from South Africa as being the most frequently isolated invasive serotype [23] . Heptavalent pneumococcal conjugate vaccine would cover almost 90% of serogroups in the United States and Canada and at least 60% of isolates in all other regions with the exception of Asia, where it covers 45% of isolates [7] . Differences between adult and pediatric isolates have been widely reported. An analysis of blood culture isolates belonging to serotypes present in the 14-valent pneumococcal polysaccharide vaccine at our institution indicated that 96% of pediatric isolates but only 72% of adult isolates were present in this vaccine [24] , and these differences have been noted as far back as the 1930s [6] . According to almost all studies that have been conducted worldwide, the coverage provided by heptavalent pneumococcal conjugate vaccine would be significantly less comprehensive in older children and adults than in young children [7] . Eighty percent of all isolates in our study were obtained from patients !2 years of age; therefore, this group represents the patients who are most likely to benefit from the new vaccine. Of note, invasive pneumococcal disease in both HIV-infected patients and patients with sickle-cell disease occurred mainly after the patients reached 2 years of age.
Our data indicate that the most common serogroups of isolates from patients infected with HIV and patients with sicklecell disease largely overlapped with those serogroups ranked with the highest frequency for the general population of children. A multicenter survey of children with sickle-cell disease indicated that 66% of 65 serotyped isolates were covered by 7V-PnC vaccine [25] . In a study from South Africa, it was found not only that serotypes of blood culture isolates from HIVpositive and HIV-negative adults were different, but also that isolates from HIV-positive adults significantly shifted toward serogroups that are common in children in South Africa (i.e., serogroups 6, 14, 19, and 23) [26] . Response to pneumococcal conjugate vaccine in HIV-infected patients is unknown at this time. Although pneumococcal polysaccharide vaccination of HIV-infected adults in Uganda failed to prevent invasive pneumococcal disease, and although serological response to vaccine was poor for these patients compared with that of uninfected controls [27] , data from a case-control study from the United States indicate a protective effect in adults that depends on the CD4 ϩ cell count at the time of vaccination [28] . A trial of the efficacy of a pneumococcal conjugate vaccine in HIV-infected children in South Africa is ongoing [29] .
Our data indicate that the serogroup distribution during the 18-year study period was very stable. Although a national surveillance study conducted in the United States during a 17-year period (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) detected only modest changes in the proportion of infections caused by most serotypes [8] , during longer periods more substantial changes in serotype distribution may occur. During the first half of the 20th century, serogroups 1, 2, and 3 were the isolates most frequently recovered at Boston City Hospital from patients of all ages [6] ; however, these serogroups accounted for !5% of isolates during 1979-1982, and serogroups 6, 14, 18, and 19 became the most common pneumococcal isolates [24] . When analyzing the serogroup distribution of blood culture isolates obtained from children at our institution during a 42-year period , it is remarkable how stable the distribution has remained. This finding contrasts with recent reports by O'Brien et al. [30] with regard to Apache and Navajo communities, where a decrease in potential vaccine coverage from 66% to 43% was documented during a 7-year period that began in 1989.
Our data allow only a limited comparison of the serogroup distribution seen with the serotypes included in the new heptavalent pneumococcal conjugate vaccine. Although the 7 most common serogroups in our study (4, 6, 9, 14, 18, 19, and 23) are identical to the serogroups of the serotypes included in the new 7-valent vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F), we did not determine the specific serotypes of our isolates, and only limited data are available that evaluate cross-reactivity of serotype-specific protection within a serogroup (e.g., 6B vs. 6A). When infants were immunized with 1 of 3 experimental pneumococcal conjugate vaccines that contain serotypes 6B and 19F but not serotype 6A or 19A, opsonophagocytic assays showed mixed results [31] . Significant increases in titers of opsonophagocytic responses to serotype 6B were observed for all 3 pneumococcal conjugate vaccines, but these increases were found for serotype 6A only with 2 vaccines. Significant increases in titers of opsonophagocytic responses to serotype 19F were shown for 2 of the 3 vaccines, but these increases were found for serotype 19A only with 1 vaccine.
In South Africa, a study of the impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine that contained serotype 6B demonstrated a significant reduction in nasopharyngeal carriage of serotype 6B but not of serotype 6A [32] . A study from Finland of the effect of 7V-PnC vaccine on acute otitis media due to pneumococci showed concordance in efficacy against serogroups 6 and 19. The rate of otitis media due to serotype 6B was reduced by 84%, and the rate of infection due to serotype 6A was reduced by 57%, whereas vaccine efficacy against both serotypes 19F and 19A was low [10] . No data for serotype cross-reactivity after conjugate vaccine in invasive pneumococcal disease are available at this time. Furthermore, the generalizability of our findings is limited, because we describe a small geographic area that might not reflect the stability of serogroups in other regions.
In summary, the serogroup distribution of invasive isolates in the pediatric population remained very stable during a 42-year period in Boston. Serogroups 4, 6, 9, 14, 18 , and 19 were the most common serotypes, and type 14 predominated. The most common serogroups isolated from CSF specimens and from patients with HIV infection or sickle-cell disease were similar to those isolated from the general population of children. Immunization of the patients in the age and risk groups targeted as priorities by the Advisory Committee on Immunization Practices [33] (all children up to 23 months of age and children 24-59 months of age with sickle-cell disease or HIV infection) should have a major impact on the rate of invasive pneumococcal infection among our population and similar populations in North America.
